Retatrutide

Research-grade retatrutide is available through peptide vendors serving the Thai market with domestic shipping. It is not available as an approved pharmaceutical product anywhere in the world yet. Phase 3 clinical trials are ongoing.

Retatrutide has produced the most weight loss of any compound in clinical trials: 28.7% in Phase 3 vs approximately 21% for tirzepatide and 15% for semaglutide. The key difference is the glucagon receptor component, which increases energy expenditure and fat burning beyond what the other compounds achieve.

Phase 2 and 3 trial data showed a manageable safety profile broadly consistent with other incretin-based therapies, though with higher GI side effect rates and a novel dysesthesia signal (abnormal touch sensations in ~21% at 12 mg). Long-term data is limited. Medical supervision is strongly recommended.

Multiple Phase 3 trials are underway with results expected throughout 2026. If successful, regulatory approval could potentially come in 2027-2028. Until then, it is only available as a research-grade compound.

Retatrutide is only available in Thailand as research-grade powder, priced per vial: roughly ฿3,500–฿4,500 for a 10 mg vial, ฿5,500–฿6,800 for 20 mg and ฿7,500–฿9,500 for 30 mg. Work out your real monthly cost from your dose rather than the vial price — at a 12 mg weekly maintenance dose you are using about 48 mg a month, so more than a 30 mg vial. There is no clinic or pharmacy price to compare against, because retatrutide is not licensed for prescription in Thailand.

Retatrutide is not stocked by Thai pharmacies or hospitals, because it is still an investigational compound awaiting approval. In Bangkok it is obtained either from research peptide vendors that ship domestically, or through a small number of private clinics running supervised peptide programmes. Clinic access is the safer route: you get medical oversight and a verified supply chain. Vendor supply is cheaper but quality varies entirely by vendor, so insist on a third-party COA for the specific batch.

Vial size is the main lever — 10 mg, 20 mg and 30 mg vials get progressively cheaper per milligram, so buying larger reduces your cost per dose. Beyond that, how far into titration you are matters enormously: a 2 mg starting dose consumes roughly a quarter of what a 12 mg maintenance dose does. Because retatrutide supply is still constrained pre-approval, vendor prices move more than they do for semaglutide or tirzepatide, so check current rates on the vendor pages listed above.

Retatrutide is not a controlled substance in Thailand and is not scheduled under Thai narcotics law. It has not been approved by the Thai FDA (อย.) for therapeutic use, so it cannot legally be marketed or sold as a medicine. It is sold as a research chemical, which is why vendors label it "not for human consumption". Personal possession is not criminalised, but you carry the full risk of an unapproved, unverified product.